Results 261 to 270 of about 64,427 (282)

Imatinib mesylate in the treatment of chronic myeloid leukaemia [PDF]

Expert Opinion on Pharmacotherapy, 2003
Imatinib mesylate (Gleevec, Glivec), formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML.
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

Pediatric Blood & Cancer, 2010
AbstractDermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet‐derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is ...
Saskia L. Gooskens, Marry M. van den Heuvel-Eibrink, Jan C. den Hollander, Cees P. van de Ven, Leon N.A. van Adrichem, Arnold P. Oranje, Flora B. de Waard-van der Spek   +6 more
openaire   +3 more sources

Imatinib Mesylate

Clinical Journal of Oncology Nursing, 2002
Kathy Wilkinson, Monica P. Davey
openaire   +2 more sources

Solubility measurement of a chemotherapeutic agent (Imatinib mesylate) in supercritical carbon dioxide: Assessment of new empirical model

Journal of Supercritical Fluids, 2019
G. Sodeifian, Fariba Razmimanesh, S. A. Sajadian   +2 more
semanticscholar   +1 more source

Epigenetic Silencing and Resistance to Imatinib Mesylate in CML [PDF]

, 2004
Abstract : Resistance to Imatinib mesylate is emerging as a real clinical problem in the management of chronic myelogenous leukemia (CML). In this project, we are exploring the hypothesis that epigenetic silencing associated with promoter DNA methylation mediates resistance in selected cases, and that reversal of silencing by decitabine-induced ...
openaire   +1 more source

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review

Clinical Oral Investigations, 2019
S. Oliveira, Luciana Gravito de Azevedo Branco, A. Rocha, D. Travassos, Gustavo Henrique Romani Magalhães, F. Fonseca, R. Mesquita, L. Abreu, T. D. da Silva   +8 more
semanticscholar   +1 more source

Imatinib mesylate

American Journal of Health-System Pharmacy, 2001
openaire   +3 more sources

Another Look at Imatinib Mesylate

New England Journal of Medicine, 2007
Mark W.M. Schellings, Yigal M. Pinto, Bob Löwenberg   +2 more
openaire   +3 more sources

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

Expert Review of Anticancer Therapy, 2016
F. Stagno, S. Stella, A. Spitaleri, M. Pennisi, F. Di Raimondo, P. Vigneri   +5 more
semanticscholar   +1 more source

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

Expert Opinion on Drug Safety, 2016
E. Ben Ami, G. Demetri
semanticscholar   +1 more source